Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Accenture
Boehringer Ingelheim
Queensland Health
Chubb
McKesson
Johnson and Johnson
US Department of Justice
Harvard Business School
Fuji

Generated: January 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,227,471

« Back to Dashboard

Summary for Patent: 8,227,471
Title:Treating sexual desire disorders with flibanserin
Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
Inventor(s): Borsini; Franco (Bad Waldsee, DE), Evans; Kenneth Robert (Toronto, CA)
Assignee: Sprout Pharmaceuticals, Inc. (Raleigh, NC)
Application Number:11/524,268
Patent Claims: 1. A method of treating a patient having hypoactive sexual desire disorder, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat hypoactive sexual desire disorder.

2. The method of claim 1, wherein the patient is male.

3. The method of claim 1, wherein the amount administered is between 0.1 and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

4. The method of claim 1, wherein the amount administered is between 1 and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

5. The method of claim 1, wherein the amount administered is between 2 and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

6. The method of claim 1, wherein the amount administered is in a dosage unit containing from 0.01 to 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

7. The method of claim 1, wherein the amount administered is in a dosage unit containing from 0.1 to 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

8. The method of claim 1 wherein the amount administered is in a dosage unit containing 150 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

9. The method of claim 1, wherein the amount administered is in a dosage unit containing 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

10. The method of claim 1, wherein the amount administered is in a dosage unit containing 80 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

11. The method of claim 1, wherein the amount administered is in a dosage unit containing 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

12. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof selected from the salts formed by the acids selected from the group consisting of succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

13. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with succinic acid.

14. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with hydrobromic acid.

15. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with acetic acid.

16. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with fumaric acid.

17. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with maleic acid.

18. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with methanesulphonic acid.

19. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with lactic acid.

20. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with phosphoric acid.

21. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with hydrochloric acid.

22. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with sulphuric acid.

23. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with tartaric acid.

24. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with citric acid.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Citi
AstraZeneca
Chubb
Mallinckrodt
Baxter
US Department of Justice
Argus Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot